Mike F. Hawkins

The Myth of Reserpine-Induced Depression: Role in the Historical Development of the Monoamine Hypothesis

For five decades it has been generally accepted that reserpine, an antihypertensive and antipsychotic drug, causes depression. The discovery that reserpine depletes brain monoamines was an important factor in the development of the monoamine hypothesis of depression, and it continues to be widely cited in support of this hypothesis. The present paper argues that, contrary to prevailing belief, reserpine is not depressogenic. The reason for perpetuation of this myth is reluctance to discard the monoamine hypothesis. This hypothesis ushered the modern biochemical paradigm into psychiatry and is still of great importance. It serves as a heuristic to guide research, it enhances psychiatry’s prestige, and it helps to validate and promote drug therapy for depression and other mental disorders.

Central nervous system neurotensin and feeding

A variety of evidence indicates that neurotensin may be involved in the regulation of ingestive behavior. Cerebral ventricular injections of this peptide produced a dose-dependent decrease in the food intake of food-deprived rats. The duration of the aphagia was found to be approximately 90 minutes for the highest dose employed (100 micrograms). The possibility that tolerance might develop to the aphagic effect of neurotensin was investigated. No evidence of tolerance was found after 6 consecutive days of ventricular injection. In addition to ventricular injections, 2 possible central sites of action were examined: the ventromedial nucleus of the hypothalamus and the nucleus accumbens. While microinjections of neurotensin into the nucleus accumbens did not alter food intake, ventromedial hypothalamic administration resulted in a dose-related reduction in food intake. The results are discussed in relation to the possible role of central nervous system neurotensin in the control of feeding.

Incoherence of neuroimaging studies of attention deficit/hyperactivity disorder.

Neuroimaging studies have been conducted with increasing frequency in recent years in attempts to identify structural and functional abnormalities in the brains of persons with attention deficit/hyperactivity disorder. Although the results of these studies are frequently cited in support of a biologic etiology for this disorder, inconsistencies among studies raise questions about the reliability of the findings. The present review shows that no specific abnormality in brain structure or function has been convincingly demonstrated by neuroimaging studies. Implications regarding stimulant treatment for attention deficit/hyperactivity disorder are discussed.

Evidence that the substantia nigra is a component of the endogenous pain suppression system in the rat

The present study sought to determine whether opiate receptors in the substantia nigra may mediate antinociception produced by systemic morphine. Bilateral intranigral microinjection of naloxone-HCl (0.3-10 micrograms) suppressed the antinociceptive effects of systemically administered morphine sulfate (5 mg/kg, s.c.) on the tail-flick and hot-plate tests in a dose-related manner. Injection of naloxone (3 micrograms) into the ventral tegmental area did not alter antinociception produced by systemic morphine (5 mg/kg, s.c.). These findings support the argument that the substantia nigra is an essential, and previously unrecognized, component of the endogenous pain suppression system.

Synergistic effects of dopamine agonists and centrally administered neurotensin on feeding

Several lines of evidence indicate that neurotensin may modulate the activity of dopamine systems in the central nervous system. The present study investigated the possibility that intraperitoneal injections of the dopamine agonists l-dopa and bromocriptine would alter the aphagia produced by central administration of neurotensin. It was found that neurotensin suppressed feeding in food-deprived rats when injected into the lateral ventricle or the ventromedial hypothalamus. Food intake was not affected, however, when the peptide was placed in the lateral hypothalamus. A dose-dependent aphagia was also observed following peripheral injections of l-dopa and bromocriptine. Additionally, the anorectic effect of centrally administered neurotensin was potentiated by concurrent administration of doses of l-dopa or bromocriptine which, when given alone, had no effect on food intake. The data suggest that neurotensin aphagia may be mediated by the peptides ability to increase the activity of dopamine systems in the central nervous system.

Microinjection of opioid antagonists into the substantia nigra reduces stress-induced eating in rats

Stress produced by pinching the tail has been shown to cause satiated animals to eat and to display oral stereotypies. Endogenous opioids and central dopamine systems have been implicated in the mediation of these effects. In order to test the possibility that the substantia nigra (SN) might be involved, the amount of food intake and gnawing produced by mild tail pinch were assessed following bilateral microinjections of opioid antagonists into the SN. Evaluations of nociceptive thresholds were also conducted using tail flick and hot plate tests. Eating induced by tail pinch was reduced by microinjections of the non-selective opioid antagonist naloxone (3, 10, 20 and 30 nmol) and by the mu-selective antagonist Cys2, Tyr3, Orn5, Pen7 Amide (CTOP) (1, 3 and 10 nmol). These effects on eating occurred in the absence of effects on gnawing. kappa- and delta-antagonists (10 nmol) had no effect on eating or gnawing. Naloxone did not alter either tail flick or hot-plate response latencies. The highest dose of CTOP increased response latency on the hot-plate test only. The results are interpreted as suggesting that the SN may be an important central site of action for opioid antagonists in reducing stress-induced eating. The possibility that the SN may be a central site mediating the effects of dopamine on this phenomenon is also discussed.

Bilateral intranigral microinjection of morphine and opioid peptides produces antinociception in rats

Bilateral intranigral microinjection of morphine produced dose-related and naloxone-reversible antinociceptive effects on the tail-flick and hot-plate tests. Intranigral injection of enkephalin had antinociceptive effects on both tests, and dynorphin had an antinociceptive effect on the hot-plate test. This is the first report of evidence that nigral opiate receptors may mediate antinociception.

Evidence that physical dependence on morphine is mediated by the ventral midbrain

Rats were given daily injections of increasing doses of morphine sulfate (40-100 mg/kg, s.c.), for 4 days. Twenty hours after the last injection of morphine, the animals received bilateral injections of naloxone (1-10 micrograms) into the substantia nigra, ventral tegmental area or sites 2 mm rostral, caudal or dorsal to the site in the nigra. Withdrawal signs were monitored for 20 min after the intracerebral injection. Naloxone administered into the nigra in morphine-dependent rats produced dose-dependent significant increases in wet dog shakes, irritability to touch, teeth chattering, diarrhea and locomotion, compared to morphine-dependent animals that received injections of saline into the nigra. The injection of naloxone (3 micrograms) into the ventral tegmental area of morphine-dependent animals, produced irritability to touch and diarrhea, compared to morphine-dependent controls that received saline in this region of the brain. Significant differences in withdrawal signs were observed between morphine-dependent animals, that received injections of naloxone (3 micrograms) into the nigra and those that received naloxone (3 micrograms) into the ventral tegmental area or rostral or caudal sites. No differences between the substantia nigra and the dorsal sites were observed. However, withdrawal symptoms were produced by injections of naloxone into the substantia nigra and ventral tegmental area, even when the guide cannulae were angled to avoid penetration of sites dorsal to these regions of the brain. Naloxone, injected into the ventral midbrain of non-dependent animals, produced no signs of withdrawal. These studies suggest that the ventral midbrain mediates physical dependence on morphine.

Effects of bilateral injection of GABA into the substantia nigra on spontaneous behavior and measures of analgesia

Bilateral injection of gamma-aminobutyric acid (GABA, 10-300 micrograms) into the substantia nigra (pars reticulata) of rats produced stereotyped sniffing and had an analgesic-like effect on the hot-plate but not on the tail-flick test. These effects of GABA (30 micrograms) were suppressed by simultaneous administration of a sub-convulsant dose of bicuculline methiodide (100 ng). Significant increases in locomotion occurred when GABA (300 micrograms) was injected along with the inhibitor of GABA-transaminase, d,l-gamma-vinyl-GABA (GVG; 5 micrograms) and the inhibitor of the uptake of GABA, 1-2,4-diaminobutyric acid (DABA; 5 micrograms). No other behavioral effects were observed following injection of GABA into the nigra, either alone or in combination with GVG and DABA. Bilateral injection of bicuculline (100-600 ng) into the nigra had strong convulsant actions. When injected simultaneously with bicuculline, GABA reduced bicuculline-induced seizures. These results are discussed in terms of their relevance to understanding the mechanisms that underlie the behavioral effects produced by injection of muscimol into the nigra.

Further studies of the effects of intranigral morphine on behavioral responses to noxious stimuli

Bilateral intranigral microinjection of morphine produces dose-related and naloxone reversible analgesic-like effects on the hot-plate and tail-flick tests. The main objectives of the present studies were to further characterize the analgesic-like effects of intranigral morphine, to determine whether these effects were related to a general impairment of sensory or motor function, and to assess their anatomical specificity. The principal findings are: (1) intranigral morphine (10 micrograms) suppresses pain-related behavior without altering responses to a variety of non-noxious auditory, visual, and somatic stimuli, and without producing motor impairment; (2) movement of injector needles approximately 1 mm rostral, dorsal, or medial to the active nigral site significantly reduces the analgesic-like effect of morphine on the tail-flick test; and (3) electrolytic lesions confined to the nigra significantly reduced the analgesic-like effect of morphine on the hot-plate test. It is concluded that the analgesic-like effects of intranigral morphine are mediated by the substantia nigra and that these effects are specifically related to pain.